VivoSeq
Other

PMD

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

PMD is an early-stage landscape with 0 programs across 2 companies. The most active players are Chiesi Farmaceutici S.p.A., AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed8 · 89%
Unknown status1 · 11%

Clinical Trials

Trial Activity

9 trials

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)
Completed·Chiesi Farmaceutici S.p.A. logoChiesi Farmaceutici S.p.A.·Phase 1·NCT05830071·95 enrolled
Gemini Symbicort pMDI
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT00646516·615 enrolled
Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT00658255·175 enrolled
Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD
Completed·—·Phase 1·NCT02395029·5 enrolled
Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers
Completed·Chiesi Farmaceutici S.p.A. logoChiesi Farmaceutici S.p.A.·Phase 1·NCT00777595·47 enrolled
Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of Mild to Moderate ED
Completed·—·Phase 1·NCT02398370·8 enrolled
Pharmacokinetic Clinical Study of CHF1535 NEXT DPI® Versus CHF1535 pMDI
Completed·Chiesi Farmaceutici S.p.A. logoChiesi Farmaceutici S.p.A.·Phase 2·NCT01349257·24 enrolled
Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)
Completed·Chiesi Farmaceutici S.p.A. logoChiesi Farmaceutici S.p.A.·Phase 2·NCT01343745·18 enrolled
Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)
Unknown status·AAllergy and Asthma Center of El Paso·Phase 4·NCT00867737·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)